
ATAI Stock Forecast & Price Target
ATAI Analyst Ratings
Bulls say
AtaiBeckley is well-positioned for success in the mental health treatment space, with its promising pipeline of novel therapies and strategic acquisitions such as the recent deal with Eli Lilly. BPL-003, the company's lead asset, has a strong potential to address the unmet needs of treatment-resistant depression with its short treatment duration and potential retreatment flexibility. Additionally, the company's management is focused on practical differentiation and commercial practicality, further emphasizing their potential for success in the market.
Bears say
AtaiBeckley is facing potential setbacks in its clinical pipeline, with the 8mg dose of BPL-003 demonstrating low efficacy and VLS-01 requiring strong results in Phase 3 to justify further investment. Furthermore, management's decision to reduce the number of participants in the Phase 2 trial of VLS-01 signals potential concerns about its effectiveness, and the overall package for BPL-003 may not be enough to satisfy regulatory standards.
This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.
ATAI Analyst Forecast & Price Prediction
Start investing in ATAI
Order type
Buy in
Order amount
Est. shares
0 shares